Combined high versus low mRNA levels of CYTH2‐ARF6‐AGAP1 provided the most robust 17‐month different in survival of ovarian cancer patients, which occurred in patients with an PI3K‐AKT signature. The gene discussed is ARF6; the disease is ovarian cancer.